Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: D0816C00002/Solo 2 A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platin

 


D0816C00002/Solo 2 A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platin


Trial Focus

Ovarian Cancer

Objective

         This is a clinical trial of investigational drug Olaparib which will be administered orally.

IRB Protocol #

13-2969

Trial Status

OPEN

Principle Investigator

KIAN BEHBAKHT

Sponsor

AstraZeneca

Contact

REBECCA KISSANE at (720)848-7202 or REBECCA.KISSANE@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. You will take two doses of study medication per day. For about the first year we will ask you to come to clinic visits very regularly, about every month. After this time, if you are doing well on study medication, you will come to the clinic about every 3 months. When you have stopped taking the study drug you will have two clinic visits. // Eligibility criteria include but are not limited to 18 years or older with ovarian cancer.Eligibility criteria include but are not limited to 18 years or older with ovarian cancer.